Janssen Research & Development, Llc

This study tests two drug combinations for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). One group gets a new drug (amivantamab) plus a targeted pill (lazertinib) as their first treatment. Another group gets amivantamab with c…

This study tests a subcutaneous (under-the-skin) form of the drug amivantamab in people with advanced EGFR-mutated non-small cell lung cancer. About 520 participants will receive the drug in different combinations to see if it shrinks tumors and how safe it is. The goal is to con…

This study follows people who already received an eye injection of JNJ-81201887 or a sham in earlier trials for geographic atrophy, a form of advanced age-related macular degeneration. The goal is to check long-term safety by monitoring eye health and side effects over time. Abou…

This study tests a drug called nipocalimab in adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder that causes weakness and numbness. The goal is to see if nipocalimab can delay or prevent relapses compared to a placebo. About 201 participants wi…

This study is a global registry that will follow about 175 pregnant people who are at risk for hemolytic disease of the fetus and newborn (HDFN), a condition where the mother's and baby's blood types don't match, causing the baby's red blood cells to break down too fast. Research…

This study follows about 295 people with multiple myeloma who have already received the cell therapy cilta-cel. The goal is to watch for delayed side effects, such as new cancers, nerve problems, or serious infections. No new treatment is given—participants are simply monitored o…